.
MergerLinks Header Logo

Announced

Completed

Shenzhen Investment Holdings led a $147m Series C round in Hinova Pharmaceuticals.

Financials

Edit Data
Transaction Value£113m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Sources

Edit

Tags

Edit

Acquisition

Completed

Private Equity

Private

Pharmaceuticals

Venture Capital

pharmaceutical company

Single Bidder

Domestic

China

Minority

Friendly

Synopsis

Edit

Investment company Shenzhen Investment Holdings led a $147m Series C round in Hinova Pharmaceuticals, a Chengdu-based drug research firm, with participation from Huarong Rongde Asset Management, Hangzhou Tigermed, and Sinopharm-CICC Capital. The financing capital will be used to support multi-center clinical trials and to commercialize the firm’s drug candidates locally and internationally.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US